- Home
- GBX vs TARS Comparison
GBX vs TARS Comparison
Compare GBX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- TARS
- Stock Information
- Founded
- GBX 1974
- TARS 2016
- Country
- GBX United States
- TARS United States
- Employees
- GBX N/A
- TARS N/A
- Industry
- GBX Railroads
- TARS Medicinal Chemicals and Botanical Products
- Sector
- GBX Industrials
- TARS Health Care
- Exchange
- GBX Nasdaq
- TARS Nasdaq
- Market Cap
- GBX 1.4B
- TARS 1.7B
- IPO Year
- GBX N/A
- TARS 2020
- Fundamental
- Price
- GBX $47.15
- TARS $57.63
- Analyst Decision
- GBX Hold
- TARS Strong Buy
- Analyst Count
- GBX 2
- TARS 7
- Target Price
- GBX $59.50
- TARS $67.14
- AVG Volume (30 Days)
- GBX 268.1K
- TARS 630.9K
- Earning Date
- GBX 10-22-2025
- TARS 08-06-2025
- Dividend Yield
- GBX 2.74%
- TARS N/A
- EPS Growth
- GBX 88.14
- TARS N/A
- EPS
- GBX 7.10
- TARS N/A
- Revenue
- GBX $3,533,700,000.00
- TARS $295,521,000.00
- Revenue This Year
- GBX N/A
- TARS $33,170.29
- Revenue Next Year
- GBX N/A
- TARS N/A
- P/E Ratio
- GBX $6.57
- TARS N/A
- Revenue Growth
- GBX 0.70
- TARS 254.45
- 52 Week Low
- GBX $37.77
- TARS $27.18
- 52 Week High
- GBX $71.06
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- GBX 52.50
- TARS 69.92
- Support Level
- GBX $45.44
- TARS $57.00
- Resistance Level
- GBX $47.50
- TARS $59.76
- Average True Range (ATR)
- GBX 1.02
- TARS 1.74
- MACD
- GBX 0.14
- TARS -0.26
- Stochastic Oscillator
- GBX 69.23
- TARS 67.78
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.